Oculis Holding AG

Equities

OCS

CH1242303498

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 03:30:00 14/06/2024 am IST			5-day change	1st Jan Change
11.8 ^USD	0.00%		-0.42%	+5.08%

11/06	BofA Securities Adjusts Oculis Holding AG to $20 From $21, Maintains Buy Rating	MT
11/06	Baird Adjusts Price Target on Oculis Holding to $37 From $35, Maintains Outperform Rating	MT

Oculis Holding - Increase in share capital

May 21, 2024 at 07:00 pm IST

With reference to an announcement published by Oculis Holding. (symbol: OCS) on May 17, 2024, the total nominal value of the company's listed share capital on Nasdaq Iceland hf. will be increased on May 22, 2024.

ISIN	CH1242303498
Company name	Oculis Holding
Total share capital before the increase	45.443.700 shares
Increase in share capital	1.000.000 shares
Total share capital following the increase	46.443.700 shares
Nominal value of each share	1 kr.
Symbol	OCS
Orderbook ID	332930

Latest news about Oculis Holding AG

BofA Securities Adjusts Oculis Holding AG to $20 From $21, Maintains Buy Rating	11/06	MT
Baird Adjusts Price Target on Oculis Holding to $37 From $35, Maintains Outperform Rating	11/06	MT
HC Wainwright Adjusts Price Target on Oculis Holding to $30 From $28, Maintains Buy Rating	11/06	MT
Oculis Sees Favorable Topline Results in Study of Potential Dye-Eye Disease Treatment	10/06	MT
Oculis Holding AG Announces Positive Topline Results of Phase 2b RelieF Trial with Licaminlimab Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy	10/06	CI
Oculis Holding AG Announces Board and Committee Appointments	30/05	CI
Oculis Holding AG announced a financing transaction	30/05	CI
Oculis Holding AG Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
H.C. Wainwright Adjusts Price Target on Oculis Holding to $28 From $29, Keeps Buy Rating	24/04	MT
Oculis Holding AG(NasdaqGM:OCS) added to OMX Nordic All-Share Index	24/04	CI
Oculis Completes $59 Million Direct Offering of Shares	22/04	MT
Oculis Holding AG Strengthens its Executive Leadership Team with the Appointment of Snehal Shah as President of Research & Development	10/04	CI
Oculis Holding Ag Announces Positive Results from Phase 3 Optimize-1 Trial of Once Daily Ocs-01 for the Treatment of Inflammation and Pain Following Cataract Surgery	08/04	CI
Oculis Holding Files $300 Million Mixed-Securities Shelf Registration	01/04	MT
Baird Adjusts Price Target on Oculis to $35 From $64, Maintains Outperform Rating	19/03	MT
Oculis Narrows Q4 Loss, Improves Cash Position -- Shares Fall	18/03	MT
Oculis Holding AG Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	18/03	CI
Oculis Holding AG Announces Executive Appointments	28/02	CI
Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery	20/12	CI
Oculis Holding AG Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema	18/12	CI
Oculis Evaluating First Patient in Phase 2b Trial	07/12	MT
Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNF ALPHA> Licaminlimab (OCS-02) in Dry Eye Disease	07/12	CI
Chardan Initiates Oculis Holding With Buy Rating, Price Target is $30	05/12	MT
Oculis Holding AG announced that it has received $71.18891 million in funding from a group of investors	15/11	CI
Oculis Says Phase 3 Stage 1 Trial of Diabetic Macular Edema Drug Candidate Met Primary, Secondary Endpoints	10/23/10	MT

Chart Oculis Holding AG

Duration

Period

More charts

Company Profile

Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.

Sector

Biotechnology & Medical Research

Calendar

14/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Oculis Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.52 CHF

Average target price

25.97 CHF

Spread / Average Target

+146.90%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
OCULIS HOLDING AG	+5.08%	493M
MODERNA, INC.	+40.80%	53.67B
LONZA GROUP AG	+35.79%	38.86B
IQVIA HOLDINGS INC.	-8.05%	38.76B
CELLTRION, INC.	-8.98%	27.27B
ICON PUBLIC LIMITED COMPANY	+10.69%	25.91B
ALNYLAM PHARMACEUTICALS, INC.	-16.21%	20.29B
UNITED THERAPEUTICS CORPORATION	+31.00%	12.78B
MEDPACE HOLDINGS, INC.	+28.51%	12.18B
BIO-TECHNE CORPORATION	-1.67%	11.96B

Other Biotechnology & Medical Research